SOURCE: Organetix, Inc.

May 03, 2005 11:05 ET

Organetix, Inc. Announces Genotoxic Study Confirms A4+L Liver Product Is Safe on Human DNA

Results of Genotoxic Study Are Based on Recent Comet Assay Testing

NEW YORK, NY -- (MARKET WIRE) -- May 3, 2005 -- Organetix, Inc. http://www.organetixinc.com (OTC BB: OGTX) today announced the results from a recent one hundred cell study which was designed to investigate the possible genotoxicity of A4+L liver product. The test focused on the primary culture of human lymphocytes using the Comet Assay to evaluate the damage to the genetic material.

The study concluded that our A4+L liver product doesn't induce damage to the DNA in human lymphocytes. The results are a positive step in evidencing the A4+L liver product is safe for human consumption.

About Organetix, Inc.

Organetix, Inc. (www.organetixinc.com) is a biotechnology company that is in the process of treating patients with a unique nutraceutical that appears to relieve symptoms of Hepatitis C. Organetix has the exclusive worldwide rights for this nutraceutical product. Hepatitis C is a life-threatening, blood-borne, liver disease that is caused by a virus. It is estimated that millions of individuals worldwide are infected with Hepatitis C making it one of the greatest public health threats faced in recent years.

Statements contained in this press release, which are not historical facts, are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties beyond the Company's control, including but not limited to economic, competitive and other factors affecting the Company's operations, management team effectiveness, expansion strategies, available financing, market prices and recovery costs, government regulations involving the Company, facts and events not known at the time of this release, and other factors discussed in the Company's filings with the Securities and Exchange Commission.

These statements are not guarantees of future performance and readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update publicly any forward-looking statements.

Contact Information

  • Contact:
    Corporate Communications Group, Inc.
    David Pomerantz
    516-791-0000 ext. 102
    david@ccgnewyork.com